Nobody briefs you on this decade. You get a briefing before a deployment. You get a briefing before a flight. You do not get one before the years between 45 and 60, which is strange, because the research says those are the years that set the terms for everything after them.
I want to be careful here. This is not a scare story. It is closer to a readiness check. The evidence does not say you are running out of time. It says the decisions you make inside this window compound — and compounding is the most powerful force any of us has.
Start with the brain, because it is the organ people fear losing most.
In July 2024, the Lancet standing Commission on dementia published its update. It named 14 modifiable risk factors and calculated that addressing all of them could prevent or delay 45% of dementia cases worldwide. That is not a projection from a wellness company. It is a population attributable fraction — 45.3% before rounding — built from relative risks and prevalence data and published in open view so other researchers can argue with it.
Here is the part nobody puts on the poster. The Commission sorts those 14 factors by life stage: early life, midlife, later life. Ten of the fourteen sit in the midlife row.
Those ten, with the weighted share of dementia risk the Commission assigns to each: hearing loss, 7%. High LDL cholesterol, 7%. Depression, 3%. Traumatic brain injury, 3%. Physical inactivity, 2%. Smoking, 2%. Diabetes, 2%. High blood pressure, 2%. Obesity, 1%. Excessive alcohol, 1%.
Add the midlife row and you are looking at roughly thirty of the forty-five points. One life stage. Ten items. Most of them things your clinician already measures and most people already ignore.
Read the list again and notice what is on it. Hearing loss is the single largest factor on the whole table. Cholesterol ties it. Neither of those is what people picture when they picture dementia prevention, which usually involves crossword puzzles.
It is never too early or too late to reduce dementia risk.2024 report of the Lancet standing Commission on dementia
Then there is the question of how much time this actually buys, which is a far better question than whether it buys any.
Researchers using the Atherosclerosis Risk in Communities study followed 12,409 adults who were free of dementia at age 55 — average age 56 at enrollment — for roughly 26 years, and counted dementia-free years between 55 and 95. People with none of three midlife risk factors — high blood pressure, diabetes, smoking — averaged 30.1 dementia-free years. People with all three averaged 17.5. One risk factor: 26.3. Two: 21.0.
Nearly thirteen years. That is the spread between the top and the bottom of that table, and the three variables separating them are the three your annual physical is already looking at.
45% of dementia cases potentially preventable by addressing 14 modifiable risk factors — and 10 of those 14 are midlife factors — source
30.1 vs 17.5 dementia-free years between 55 and 95, for adults with none versus all three of: hypertension, diabetes, smoking (ARIC, 12,409 participants) — source
52.7% of U.S. midlife adults report two or more chronic conditions — about 63.8 million people — source
Now the uncomfortable part, which is where most Americans actually sit.
CDC researchers analyzing Behavioral Risk Factor Surveillance System data through 2023 found that 52.7% of midlife adults — roughly 63.8 million people — reported two or more chronic conditions. 78.4% reported at least one. The three most common were obesity at 37.1%, high cholesterol at 36.9%, and high blood pressure at 35.0%.
Hold those three against the Lancet midlife row. They are the same conditions. The thing that will shape your cognition at 78 is sitting in your chart at 52, and in most cases it already has a name and a treatment.
Mortality tells the same story in blunter numbers. In 2023, among Americans aged 45 to 54, the three largest causes of death were cancer (32,867 deaths), unintentional injury (30,559) and heart disease (30,430). From 55 to 64, cancer took 101,714 lives and heart disease 79,726. Diabetes killed 15,958 people in that decade. Liver disease killed 14,764.
These are not diseases of old age. They are diseases of midlife that get counted in old age.
So what do you do with it.
I spent 22 years in the Air Force and retired as a Senior Master Sergeant. What that gives you is not courage. It gives you a relationship with checklists. You do not inspect an aircraft because you expect it to fail. You inspect it because the cost of a missed item is wildly out of proportion to the effort of checking.
Midlife is an inspection interval. Blood pressure. A lipid panel where you actually know your LDL number. An A1c. A real audiogram, not a test of whether you can hear your phone. Treatment for depression, if depression is the honest answer. A helmet, every time, because traumatic brain injury carries the same 3% as depression on that table. These are small, dull, repeatable items. The research says dull and repeatable is what moves the thirty-year number.
I came into this subject from the other direction.
I was in a wheelchair with a rare form of rheumatoid arthritis. I went on to run 28 marathons and a 50-miler. I am not going to hand you that as a prescription, because it is not one, and I am not a clinician. What I will tell you is that it taught me what the research keeps confirming: the body responds to what you ask of it, later than almost anyone expects, and the asking does not have to be dramatic. It has to be consistent.
That is where my whole method comes from. Thirty-four minutes a day, every day, is a different intervention than four hours on a Saturday. Not because thirty-four is a magic number — because daily is.
One more thing, and it is the thing I actually want you to take with you.
This decade is not your last chance. It is your highest-leverage one. The gap between 30.1 dementia-free years and 17.5 is not willpower and it is not luck. It is a short list of measurable things, checked on a schedule, treated when they come back off.
You were handed a window nobody explained to you. Now somebody has.
Most people think of muscle as something you have for appearance, or for carrying groceries. That is roughly like thinking of your liver as the thing that gives your abdomen its shape.
Muscle is an organ. It has a metabolic job and an endocrine job, and when it shrinks, those jobs shrink with it. That is the part that decides whether you are independent at 80, and it is the part almost nobody discusses, because it is invisible in a mirror.
Start with blood sugar, because it is the cleanest illustration.
When researchers infuse glucose and insulin under controlled clamp conditions, skeletal muscle takes up 80 to 90% of that glucose. After an ordinary meal, muscle is responsible for more than 80% of the disposal of an oral glucose load. Your muscle is the warehouse. Insulin is the delivery instruction. If the warehouse gets smaller and less responsive, the glucose stays in circulation — and over years, that is how type 2 diabetes gets built.
So when you read that resistance training improves insulin sensitivity, that is not a soft wellness claim. It is a statement about the size and quality of the tissue that handles most of your carbohydrate.
Then there is the endocrine side, which is newer and more interesting.
Fat tissue got reclassified as an endocrine organ once researchers identified adipokines — the signalling molecules it secretes. The same reclassification has happened to muscle. Contracting muscle releases molecules called myokines, which act locally and travel through the bloodstream to speak to other tissues. Reviews of this literature describe myokines increasing insulin sensitivity, improving glucose disposal, and participating in the regulation of glucose and lipid metabolism — and describe skeletal muscle acting as an endocrine organ that releases these molecules to coordinate with the rest of the body.
Read it plainly. When you contract muscle, it sends chemical messages to the rest of you. When you stop, those messages stop. That mechanism is still being mapped, and it is the strongest available answer to the question of why strength work helps things that appear to have nothing to do with strength.
When you contract muscle, it sends chemical messages to the rest of you. When you stop, those messages stop.
Now the arithmetic of losing it.
Muscle mass declines roughly 3 to 8% per decade after age 30, and the rate accelerates after 60. That is a very quiet number. Across the 45-to-60 window it means you can lose on the order of a tenth of your muscle without a single symptom you would think to mention to a doctor. You notice it as the stairs feeling different. You attribute it to age — technically correct, practically useless.
What makes it worse is that the loss is not evenly distributed. Strength falls faster than mass, and power — strength expressed quickly — falls faster than strength. Power is what catches you when you trip.
80-90% of infused glucose is taken up by skeletal muscle in clamp studies; muscle handles over 80% of an oral glucose load — source
3-8% muscle mass lost per decade after age 30 — accelerating after 60 — source
30-60 min per week of muscle-strengthening activity: the dose where pooled cohort data show maximum risk reduction — source
1.2 g/kg per day: the protein requirement for older adults estimated by indicator amino acid oxidation — about 40% above the current RDA — source
It helps to know that this has a name, a diagnosis, and stages.
Sarcopenia is the age-related loss of muscle mass, strength and function. In 2019 the European Working Group on Sarcopenia in Older People published a revised consensus — EWGSOP2 — that changed the diagnostic order in a way clinicians still find clarifying. Strength, not mass, became the primary indicator. Mass confirms the diagnosis. It no longer leads it.
How sarcopenia is staged (EWGSOP2, 2019)
Probable sarcopenia — low muscle strength. That finding alone is enough to begin treating, before anything is confirmed on a scan.
Confirmed sarcopenia — low muscle strength plus low muscle quantity or quality.
Severe sarcopenia — low strength, low mass, and measurably impaired physical performance.
Why that order matters: strength is cheap to measure and it moves first. You can meet the definition of probable sarcopenia and start treatment while the loss is still easy to reverse. That is a screening opportunity sitting in plain sight, and the decade to use it in is exactly the one this issue is about.
The treatment, by the way, is not a drug. It is load and protein.
So what is the dose. This is the question I get most, and the honest answer is smaller than people fear.
The federal Physical Activity Guidelines for Americans ask adults to do muscle-strengthening activity of moderate or greater intensity, involving all major muscle groups, on two or more days a week. That is the floor, and it is not aspirational.
A 2022 systematic review and meta-analysis in the British Journal of Sports Medicine pooled 16 cohort studies and found muscle-strengthening activity associated with a 10 to 17% lower risk of all-cause mortality, cardiovascular disease, total cancer, diabetes and lung cancer. The dose-response was not linear. Maximum risk reduction — roughly 10 to 20% — appeared at about 30 to 60 minutes a week, with the lowest all-cause mortality around 40 minutes a week, and no clear additional benefit past an hour.
Forty minutes. A week. For the largest observed mortality benefit in the pooled data.
Which makes the adherence numbers hard to look at.
In 2020, 24.2% of American adults met the Physical Activity Guidelines for both aerobic and muscle-strengthening activity. Among adults aged 50 to 64 it was 21.6% of men and 17.6% of women. Among adults 65 and over, 15.3% of men and 10.8% of women.
So roughly four out of five people in the decade where muscle matters most are not doing the thing that protects it, at a dose that would fit inside two television episodes a week.
Protein is the other half, and the recommendations have genuinely moved.
The Recommended Dietary Allowance is 0.8 grams of protein per kilogram of body weight per day, and it is the same number for a 25-year-old and a 75-year-old. Researchers using the indicator amino acid oxidation method have estimated the actual requirement for older men and women at about 1.2 g/kg/day — roughly 40% higher than the current recommendation on a body-weight basis.
The PROT-AGE study group, writing in the Journal of the American Medical Directors Association, recommended at least 1.0 to 1.2 g/kg/day for people over 65 to maintain and regain lean mass and function; 1.2 g/kg/day or more for those exercising and otherwise active; and 1.2 to 1.5 g/kg/day for most older adults living with acute or chronic illness.
There is also a distribution problem, and it is the one most people get wrong.
The aging body shows what researchers call anabolic resistance — decreased sensitivity of skeletal muscle to ingested protein. The same gram of protein does less work than it used to. Reviews of this literature point toward a moderate serving of high-biological-value protein at each meal, on the order of 30 grams providing about 12 grams of essential amino acids, with a high proportion of leucine.
Practically, that means protein at breakfast. Which is where almost everyone fails. Most people eat 10 grams in the morning, 20 at lunch, and 60 at dinner, and the body cannot bank it.
Put it together and the picture is unromantic in a way I find encouraging.
Two sessions a week. Thirty to sixty minutes, total. All the major muscle groups. Enough protein, spread across the day instead of piled into one meal. That is the intervention that protects the organ handling most of your blood sugar, manufacturing signals for the rest of your body, and deciding whether you can get up off the floor at 82.
I am not going to tell you it is easy to start. I will tell you it is small. I came back from a wheelchair, and the first part was not the marathons. The first part was a dose I could repeat tomorrow. That is still the only part that matters.
I am going to write this one carefully, and I want to tell you why before I start.
Nothing in this piece is medical advice. I am not a clinician. What follows is a description of what the published evidence says, where it is strong, where it has been revised, and where it is genuinely unresolved. Every decision in it belongs to you and the clinician you trust.
I am writing it because the most common thing I hear from women in this decade is not a question about hormones. It is a sentence: nobody will tell me anything.
Start with the timeline, because a surprising number of women have never been given it.
The average age of menopause in the United States is 52. The transition leading up to it — perimenopause — usually begins somewhere between 45 and 55 and can run for several years. You only know you have reached menopause after twelve consecutive months without a period. Everything before that twelve-month mark is the transition, and the transition is where most of the symptoms live.
How long do the symptoms last. The Study of Women's Health Across the Nation followed 3,302 women across seven U.S. sites and found the median total duration of frequent hot flashes and night sweats was 7.4 years. For the subset of women with a clearly identified final menstrual period, a median of 4.5 years of symptoms came after that period. African American women reported the longest median duration, at 10.1 years.
Seven years is not a phase. It is a seventh of an adult working life.
Now 2002, because everything since runs through it.
The Women's Health Initiative was the largest randomized trial ever run on postmenopausal hormone therapy. In 2002 its investigators reported the principal results of the arm testing conjugated equine estrogens plus medroxyprogesterone acetate against placebo, after an average of 5.2 years. The conclusion, as a population average, was that overall health risks exceeded benefits for using that combination to prevent chronic disease in healthy postmenopausal women. Breast cancer, stroke, coronary events and clots went up. Colorectal cancer and hip fracture went down. The arm was stopped early.
What happened next was not a scientific event. It was a communications collapse. Prescriptions fell off a cliff worldwide, and a generation of women — and a generation of clinicians trained in that aftermath — absorbed one sentence: hormones cause breast cancer.
The reappraisal did not come from marketing. It came from the same researchers reading their own data more carefully, and the central issue is age.
The women randomized to estrogen plus progestin in the WHI had a mean age of 63. That is roughly eleven years past the average age of menopause. The trial was designed to test chronic disease prevention in older postmenopausal women, and it answered that question well. It was then applied to 51-year-olds with night sweats — which was never the question it asked.
That observation became what researchers call the timing hypothesis: that the benefit-risk balance of hormone therapy depends heavily on how old a woman is, and how far from menopause she is, when she starts. Twenty-plus years of subgroup analyses, meta-analyses and extended follow-up have been spent testing it, and the current guidance reflects it.
The 2022 hormone therapy position statement of The North American Menopause Society — now The Menopause Society — is the document to know. It was developed by an advisory panel of clinicians and researchers in women's health and menopause, approved by the society's board, and endorsed by dozens of national and international medical societies.
Its central statement: for women younger than 60, or within 10 years of menopause onset, with no contraindications, the benefit-risk ratio is favorable for treating bothersome vasomotor symptoms and for preventing bone loss. For women who initiate therapy more than 10 years from menopause onset, or who are older than 60, the statement says the benefit-risk ratio appears less favorable, because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia.
One guideline. Two different answers. Separated by when you start.
7.4 years median total duration of frequent hot flashes and night sweats; 10.1 years median for African American women (SWAN, 3,302 women) — source
mean age 63 of the women randomized to estrogen plus progestin in the WHI — about eleven years past the average age of menopause — source
75% reduction in weekly vasomotor symptom frequency versus placebo; the position statement notes no other pharmacologic or alternative therapy has been found to provide more relief — source
9 per 10,000 additional breast cancer cases per person-year of continuous combined estrogen plus progestin in the WHI; estrogen alone showed 7 fewer invasive cases per 10,000 person-years — source
Absolute numbers are more useful than relative ones, so here are the published absolute numbers.
In the WHI, continuous combined estrogen plus progestin produced nine additional breast cancer cases per 10,000 person-years of therapy. The position statement describes that attributable risk — in a trial population of mean age 63 — as less than one additional case per 1,000 users annually, and sets it beside the risk observed with obesity and with low physical activity. The elevated hazard ratio for that combination persisted at a median 20 years of cumulative follow-up.
Estrogen alone went the other direction. Women with a hysterectomy who received conjugated equine estrogens alone had seven fewer invasive breast cancers per 10,000 person-years — a non-significant reduction at 7.2 years that became statistically significant at a median 20 years of follow-up.
For stroke, among women who started under 60 or within 10 years of menopause, the attributable risk in the WHI was rare — under 10 per 10,000 person-years — and not statistically significant for the combination, with an absolute figure of 5 per 10,000 person-years. For type 2 diabetes, the combination produced 16 fewer cases per 10,000 person-years and estrogen alone 21 fewer.
Now the honest part, which is the reason I wanted to write this at all. A great deal is still unresolved, and the position statement says so plainly rather than burying it.
Hormone therapy is not government approved for the prevention of cardiovascular disease.
The statement says hormone therapy is not recommended at any age to prevent or treat a decline in cognitive function or dementia. The WHI Memory Study found that starting estrogen plus progestin after age 65 doubled the risk of all-cause dementia — an additional 23 cases per 10,000 person-years. Starting late is not the same as starting early, and nobody should read the timing hypothesis as a clean bill of health.
No large randomized trial has assessed long-duration use, so questions about taking hormone therapy for fifteen or twenty years are unanswered, not answered reassuringly. There are no head-to-head randomized comparisons of oral versus transdermal therapy, which means the widely repeated claim that patches carry less clot and stroke risk rests on observational data. Data are described as insufficient for long-term use in perimenopausal women and in postmenopausal women under 50. And blood or saliva hormone testing is called unreliable and not recommended for tailoring therapy.
An arbitrary age-based stopping rule is not clinically appropriate.The 2022 hormone therapy position statement of The North American Menopause Society
Some things are less contested than the public conversation suggests.
Genitourinary syndrome of menopause — vaginal dryness, burning, irritation, pain with sex, urinary urgency, recurrent urinary tract infections — is effectively treated by low-dose vaginal estrogen, with minimal systemic absorption. The statement says vaginal therapy is preferred over systemic therapy when estrogen is being used only for genitourinary symptoms, that a progestogen is not required alongside it, and that it may be considered at any age and for extended duration if needed. Non-estrogen options approved for painful sex include ospemifene and intravaginal DHEA.
And on stopping: because many women have bothersome symptoms for many years, the statement says long-duration use may be needed, and that an arbitrary age-based stopping rule is not clinically appropriate. There are no data supporting routine discontinuation at 65. Up to 8% of women continue to have hot flashes 20 years or more after menopause; in one Swedish study of women over 85, 16% reported hot flashes at least several times a week.
Two more findings that cut against the current enthusiasm, because honesty has to run in both directions.
Systemic hormone therapy does not improve urinary incontinence, and may increase the incidence of stress incontinence. And systemic hormone therapy generally does not improve sexual function, interest, arousal or orgasmic response independent of its effect on genitourinary symptoms.
If someone is selling you systemic hormones as the answer to those two things specifically, the guideline is not on their side.
So what do you do with all of this.
You take it to a clinician who has read it. That is the entire recommendation. Not a supplement, not a protocol, not a decision made from an article — including this one.
What I want you to walk out of here with is a different posture. You are not asking for a favor. You are asking about a well-documented physiological transition with a median symptom duration of 7.4 years, a current guideline that stratifies by age and time since menopause, published absolute risks you are allowed to look at, and a list of things that are genuinely unknown and should be named as unknown.
Nobody would tell you anything. Now you know what to ask.
People over profit is not a discount you hand out. It is the cheaper way to operate.
You have been handed a false choice. Run a real business, or do real good. Pick one. The people who hand you that choice are usually not doing either one well. Here is what nobody says out loud: a for-profit company is the most reliable engine for funding impact anyone has built. It has revenue. It has a payroll that already clears. It has customers who already trust it. A non-profit has to raise its entire budget again every single year, from scratch, in a market where attention is the scarcest thing there is. A business earns its budget. That does not make business noble. It makes it durable. Durability is exactly what a mission needs and almost never has.
So stop asking whether you are allowed to make money while you change something. Start asking what your company is actually for, who it carries, and whether the people inside it can feel it. That last question is not soft. It is one of the most heavily measured questions in management, and the numbers are not close.
18% of U.S. employees say their current job has a purpose they personally believe in — source
20% of employees worldwide were engaged at work in 2025 — a second straight annual decline — source
23% higher profitability in top-quartile vs bottom-quartile engaged business units — source
7% share of all U.S. charitable giving that came from corporations in 2025 — source
Start with purpose, because that is the word everybody uses and almost nobody measures. Gallup surveyed 4,475 U.S. working adults in August 2025 for a study called The Power of Purpose. Only 18 percent described their current job as one that has a purpose they personally believe in. Forty-five percent said they work primarily to collect a paycheck and benefits. Then look at what purpose does once it is present. Half of the employees with strong work purpose were engaged in their jobs, against 9 percent of those with low purpose. Forty-one percent of the strong-purpose group were watching for or actively seeking a new job, against 68 percent of the low-purpose group. Thirteen percent of the strong-purpose group reported burning out very often or always, against 38 percent. Same economy. Same job market. Different reason to show up.
Now the money. Gallup's Q12 meta-analysis is the piece of research to put in front of anyone who tells you culture is a luxury. It pools 736 research studies across 183,806 business and work units, 3,354,784 employees, 347 organisations, 53 industries and 90 countries. Comparing top-quartile engagement units with bottom-quartile ones, the median differences are 23 percent in profitability, 18 percent in productivity measured by sales, 10 percent in customer loyalty and 22 percent in organisational citizenship. The avoided-cost side is bigger still: 78 percent in absenteeism, 63 percent in safety incidents, and 21 to 51 percent in turnover depending on the organisation. And 70 percent in wellbeing. Read that list again as a profit-and-loss statement, because that is what it is.
People over profit is not a discount you hand out. It is the cheaper way to operate — and the research has been saying so for twenty years.
Here is the bridge between purpose and performance, and it is narrower than you think. Gallup's work on mission-driven workplaces found that only about four in ten U.S. employees strongly agree that the mission or purpose of their company makes them feel their job is important, and only 41 percent strongly agree they understand what their company stands for. Four out of ten people can explain why your company exists. Move that even slightly and the outcomes shift: Gallup reports a 10 percent improvement in employees' connection with the mission is associated with a 12.7 percent reduction in safety incidents, an 8.1 percent decrease in turnover and a 4.4 percent increase in profitability. You do not need a new mission statement. You need the one you have to be legible to the person answering your phone.
Which brings us to the cheque, and to the most misread number in this whole conversation. Americans gave 617.20 billion dollars to charity in 2025 — the first year ever above 600 billion. Individuals gave 64 percent of it. Corporations gave 7 percent, about 43.67 billion, and corporate giving grew 3.1 percent, the slimmest growth of any source and essentially flat once you adjust for inflation. Giving USA estimates corporate giving at roughly 1 percent of corporate pre-tax profits, below the four-decade average. Sit with that. For all the noise about corporate social responsibility, the cheque is the smallest lever a business owner holds. The payroll is bigger. The culture is bigger. The customer list is bigger. The room you can fill is bigger.
The world-changer's operating checklist
Write down what the business is for in one sentence a new hire can repeat back, then test whether they can.
Pick one impact topic you will actually be measured on this year. One. Verified by someone outside the building.
Treat engagement as a cost line, not a mood: track absenteeism, turnover and safety against the quarter.
Put the mission inside somebody's job description, with a budget, or it is a poster and not a plan.
Give money last, not first. The payroll, the culture and the customer list move more than the cheque does.
Review it on a clock — three months, then a year — because milestones are what separate standards from intentions.
So here is the honest version. Impact is not what you do with the money after the business works. Impact is how the business works. The data says engaged teams earn more and cost less. The data says purpose cuts turnover intent by almost half and burnout by two thirds. The data says the mission only pays when people can actually name it. And the data says corporate cheques are about 1 percent of pre-tax profit, which means the cheque was never going to be the thing that changed anything. You already own the lever. It is payroll, it is the room you can fill, it is the list that answers when you write, and it is whether the person who works for you can tell a stranger what this is all for. Build the for-profit. Fund the mission from it. Then go home at a reasonable hour, because a founder who burns out helps nobody.
The hardest problem most non-profits have is not heart. It is distribution.
The mission is sound, the people are good, and almost nobody outside the room ever hears about it. Meanwhile the for-profit world has spent thirty years building the machinery that solves exactly that problem: production, logistics, data, follow-up, a reason for a stranger to pay attention. The machinery is not evil. It is just rarely pointed anywhere useful. So point it. What follows is three real organisations and how they stack, written plainly so you can copy the shape even if you never work with any of them. One builds the experience. One makes sure the market sees it. One is the mission the whole thing is for.
Start with the production layer. Activate 4 Impact sells one line: from big idea to red-carpet rollout. Under it, three words — Strategy, Production, Execution — and one more, worldwide. It is a R0cketShip Holdings and Crews Beyond Limits company. The build list is eight items long: retreats and offsites, events and experiences, business launch, growth and scale, teams and culture, scale and exit, real estate and development, and tourism and destination. The sectors it names are government and defence, federal agencies, non-profits and movements, and enterprise, hospitality and tourism. Krystalore Crews, MBA, is Executive Director — a 22-year Air Force veteran, retired Senior Master Sergeant, who built a 40-hour Pentagon curriculum and the computer-based training behind it used by roughly 180,000 people a year. Jeff Cline is the growth and technology architect.
That gap between those two seats is the actual insight, and it is worth saying slowly. A great room does not sell itself. Non-profits learn this the expensive way: they run a genuinely moving event, forty people leave changed, and nothing happens next because nobody captured who came, nobody followed up, and the market never found out it existed. The division of labour here is explicit. Activate creates the experience. Amplify uses growth technology so the market sees it. Two halves, deliberately separate, so neither one gets to be an excuse for the other. If your event was good and nothing came of it, you were missing the second half. If your marketing was loud and nothing came of it, you were missing the first.
Your secret weapon starts with a conversation.worldchangers.ai
The second half has a name and a front door. worldchangers.ai calls itself The Founder's Edge, a Krystalore and R0cketShip joint venture, and its headline is a sentence most founders have never been offered: People First. Tech-Backed. Change the world without needing a vacation from your life. Its three pillars are stated flatly — People First, growth that fits your life rather than the other way around; Tech-Backed, predictive data that shows who is in-market before competitors; and Change the World, scale your impact without burning out. The offer is a ladder rather than a package, and the top rung is simply called The Secret Weapon.
Then the third organisation, which is the reason the first two matter. Her Next Mission is the featured non-profit of this edition. It is a 501(c)(3) in formation — say that precisely, because it is not yet a determined 501(c)(3) and the difference is real for anyone considering a gift. It was founded by SMSgt (Ret.) Krystalore Crews, USAF. Its two public lines are From Service to Success and IT'S HER TURN. Its stated purpose is for female Veterans and first responders transitioning out of service, offering coaching, community and clarity for the next mission. The programmes named are one-to-one somatic and life coaching, group business and clarity bootcamps, multi-day immersive retreats, an annual summit and events, a podcast, and grants and donation programmes. The people it serves come out of military, fire, law enforcement and EMS.
Why this population, and why now. The Department of Veterans Affairs is blunt about the trend: more than two million women Veterans live in the United States today, and women are the fastest growing group in the Veteran population. In 2000 they were 4 percent of the Veteran population. By 2023 that was 11.3 percent, and it is projected to reach 18 percent by 2040. The median age of women Veterans was 52 in 2023 — these are not all young separations, they are women in the middle of a working life. About 930,000 were enrolled in VA health care in 2023, which is 45 percent of all women Veterans.
2.08M women Veterans in the U.S. in 2025 — 12% of all Veterans — source
4.6% vs 3.3% unemployment rate, female Veterans vs male Veterans, 2025 — source
11.3% to 18% women's share of the Veteran population, 2023 to projected 2040 — source
930,000 women Veterans enrolled in VA health care in 2023 — 45% of all women Veterans — source
The employment picture is where the gap gets measurable. The Bureau of Labor Statistics counted 2,077,000 women Veterans in 2025, 12 percent of all Veterans. The unemployment rate for female Veterans was 4.6 percent, against 3.3 percent for male Veterans — and 4.0 percent for nonveteran women. Read that triangle carefully, because it is the whole argument. Male Veterans do better than the women who served alongside them, and women Veterans do slightly worse than women who never served at all. Whatever service is doing for men on the way out, it is not doing for women. That is not a feelings problem. That is a transition-design problem, and transition design is a thing you can build.
If you run a non-profit, steal this shape
Decide which half you are missing — the room, or the follow-up. Most organisations are missing the follow-up.
Never run an event you cannot follow up on. Capture who came before you spend a dollar on the programme.
Separate the experience from the amplification on purpose, so neither can be used to excuse the other.
Attach the mission to a revenue engine that is good at something people already buy.
Say your legal status out loud — in formation means in formation — because trust compounds faster than funding.
One last thing, for the woman reading this who is six months out from her separation date and has not told anyone how lost she feels. Two million of you. The fastest-growing group in the Veteran population. Unemployed at a higher rate than the men you served beside, and at a higher rate than the women who never served at all. That is not your personal failure. It is a system that has not caught up to who serves in it, and it is being built right now by people who have been through it. From service to success is not a slogan on this page. It is the gap in the data, and somebody is finally working in it.
Start over. I want to take that phrase apart, because it is doing real damage.
When a 52-year-old says she is starting over, she almost always means starting from zero. New field, no standing, bottom rung, back of the line. That is a terrifying thing to picture. It is also not what the labor-market data describes. What the data describes is people carrying a very large asset into a new room and never putting a price on it.
Here is the asset.
The Bureau of Labor Statistics measures how long workers have been with their current employer. In January 2026 the median for all wage and salary workers was 4.1 years, up from 3.9 years in January 2024. For workers aged 25 to 34 it was 3.0 years. For workers aged 55 to 64 it was 9.6 years. Among workers aged 60 to 64, 52.6% had been with the same employer for at least ten years.
Put those numbers side by side. Three years, against nine and a half. More than half of workers in their early sixties have a decade in one place.
Nine and a half years is not a liability. It is a decade of institutional knowledge, working relationships, judgment about what actually breaks, and a demonstrated willingness to stay when staying was hard.
Every one of those is portable. None of them appear on a resume unless you deliberately put them there — and most people in this decade write their resume as a list of titles, which is the single component that does not transfer.
9.6 years median tenure with current employer for workers aged 55-64, versus 3.0 years for workers aged 25-34 (January 2026) — source
2.2 jobs average number held between ages 45 and 54, out of 12.9 jobs held across ages 18 to 58 (NLSY79, born 1957-1964) — source
19.1% of Americans aged 65 and over were in the labor force in 2025, up from 12.9% in 2000 — source
15.5% unincorporated self-employment rate for workers 65 and over, versus 4.1% for workers aged 25-34 — source
The second thing the data says is that you are not a serial changer, and you were never supposed to be.
The BLS has followed a cohort born between 1957 and 1964 since 1979, in the National Longitudinal Survey of Youth. Those individuals held an average of 12.9 jobs between ages 18 and 58. That figure gets quoted constantly as proof that modern careers are chaotic. What rarely gets quoted is the distribution. Of those 12.9 jobs, an average of 2.2 came between ages 45 and 54, and 1.3 came between 55 and 58.
Almost all the churn happens young. By midlife the pattern inverts and people go deep. So if changing direction at 50 feels unnatural, that is not a character flaw. It is an accurate reading of your own history, and of nearly everyone else's.
The third thing is the one that changes the math on whether a change is worth making at all.
In 2025, 19.1% of Americans aged 65 and over were in the labor force. In 2000 it was 12.9%. The rate peaked at 20.2% in 2019. For men 65 and over the 2025 figure was 23.1%; for women, 15.7%.
The BLS projections push further out. While the overall labor force participation rate is projected to fall from 62.6% in 2023 to 61.2% in 2033, participation for workers aged 55 to 64 is projected at 69.1% in 2033, for ages 65 to 74 at 30.4%, and for those 75 and over at 10.1%.
Run that on yourself. If you are 50 and participation at 65 to 74 is running near 30%, you are not looking at fifteen more working years. You may be looking at twenty or twenty-five. A change that takes three years to pay off is not reckless at that horizon. It is conservative.
A change that takes three years to pay off is not reckless at that horizon. It is conservative.
And a meaningful share of those later years are not spent as somebody's employee.
In BLS data, self-employment rises steeply with age. The unincorporated self-employment rate was 1.9% for workers aged 16 to 24, 4.1% for ages 25 to 34, 7.1% for 45 to 54, 8.8% for 55 to 64, and 15.5% for workers 65 and over — against an overall rate of 10.1% across all workers. The incorporated rate climbs the same way: 0.3%, then 1.6%, then 4.7%, then 5.9%, then 8.6%.
Incorporated is the detail I would underline. Incorporating is what you do when a thing has structure, revenue and a reason to exist beyond this month. Older self-employed workers are more likely to be incorporated than younger ones. The late-career business is, on average, a more serious entity than the early-career hustle.
So the reframe is not motivational. It is mechanical. You are not starting from zero. You are relocating an asset — and the work is to name that asset precisely enough to carry it across a boundary.
That is a harder exercise than updating a resume, and it takes about an hour.
The midlife inventory
Write the decade, not the title. What did you actually get good at across those 9.6 years? Not the job description — the things people came to you for when it mattered.
Name the three hardest situations you handled, and what you knew that let you handle them. That knowledge is the transferable part. The title is the part that stays behind.
List who trusts you, and why. Relationships are the slowest asset to build and the fastest to carry across a boundary.
Find the overlap. Where does what you know meet something people are already paying for? Not your passion — the overlap. Passion with no overlap is a hobby, and hobbies are fine, but do not finance them with a career change.
Pick the smallest version. A three-year payoff does not start with a three-year commitment. It starts with a block of time you can repeat tomorrow.
I will use my own career as the example, because it is the one I am allowed to describe.
I spent 22 years in the Air Force and retired as a Senior Master Sergeant. Inside that, I built a 40-hour curriculum for the Pentagon and the computer-based training that went with it — used by roughly 180,000 people a year. On paper, when I left, my title did not exist in the civilian world. Nobody was hiring a Senior Master Sergeant.
But the asset was never the title. The asset was one sentence: I can design instruction that scales to six figures of learners inside an organization that does not tolerate sloppiness. That sentence survives the boundary. The title does not.
What I built afterward — an MBA, a book that became an Amazon best seller, a somatic coaching certification, a keynote practice, Her Next Mission for women Veterans and first responders, and the executive director role at Activate 4 Impact — is not a new career. It is the same asset, relocated. Several times.
One practical note on how change actually gets made in a decade when you already have a full life.
You will not get a sabbatical. You will not get a clean quarter to think. What you get is a block, daily, that nobody is allowed to take. My own method line is the shortest version of this I know: level up life and business in 34 minutes per day.
Thirty-four minutes is not a productivity trick. It is a number small enough to survive a bad week — and surviving bad weeks is the only property that matters, because bad weeks are what kill every midlife reinvention I have watched fail. Not a lack of talent. Not a bad market. A plan that required a good month.
Nine and a half years of median tenure. An average of 2.2 job changes across an entire decade. Twenty-plus working years still ahead of a 50-year-old. A self-employment rate that keeps climbing with every age bracket.
None of that describes someone starting from zero. It describes someone who has finally accumulated something worth moving.
Two million women veterans. The fastest-growing group in the veteran population. And a transition built for somebody else.
There is a particular silence that lands about six months after separation. The structure is gone — the rank, the unit, the thing you were unambiguously good at — and what replaces it is a job search in a language you do not speak, conducted by people who read your record and ask what you did in the real world. Men feel it too. The data says women feel it harder.
The Bureau of Labor Statistics counted 2,077,000 women veterans in 2025, twelve percent of all veterans. Their unemployment rate was 4.6 percent, against 3.3 percent for male veterans — and 4.0 percent for women who never served at all. Read that triangle slowly, because it is the whole argument. Men do better leaving service than the women who served beside them, and those women do slightly worse than women with no service at all. Whatever the transition is doing for men, it is not doing for women.
2.08M women veterans in the U.S., 2025 — 12% of all veterans — source
4.6% vs 3.3% unemployment, female veterans vs male veterans — source
11.3% to 18% women's share of the veteran population, 2023 to projected 2040 — source
52 median age of women veterans in 2023 — mid-career, not retiring — source
The Department of Veterans Affairs is blunt about the trend. Women are the fastest growing group in the veteran population: four percent in 2000, 11.3 percent by 2023, and a projected eighteen percent by 2040. Their median age in 2023 was 52, which means these are not young separations tidily absorbed by a first career — they are women in the middle of a working life, with mortgages and teenagers and a resume that stops making sense at the top.
From service to success.Her Next Mission
Her Next Mission was founded by SMSgt (Ret.) Krystalore Crews, USAF, who did twenty-two years and then did the transition herself. It serves female veterans and first responders — military, fire, law enforcement and EMS — with one-to-one somatic and life coaching, group business and clarity bootcamps, multi-day immersive retreats, an annual summit, a podcast, and grant and donation programmes. The stated mission is to walk every woman through the transition no one prepared her for, until she finds the next mission worth running toward.
If you run a business and have ever said you want to do something for veterans, here is the honest version of what helps. Not a flag on your website in November. A referral. A sponsorship of one seat at one retreat. An interview with a woman whose resume you cannot immediately parse. The gap in the data above is not a feelings problem — it is a hiring problem and a transition-design problem, and both of those are things a business owner can actually move.
Most owners treat the business and the giving as two budgets and two calendars. The ones who get anywhere treat them as one.
Here is the trap. You decide you want the company to stand for something, so you bolt an impact programme onto the side of it — a committee, a day of volunteering, a cheque in December. It runs on goodwill, goodwill is the first thing a hard quarter spends, and by the second year it is a line item nobody defends. The problem was never commitment. It was architecture. The impact was built as a cost rather than as part of what the business already does well.
The alternative is to point the machinery you already own at it. You have a payroll that clears, customers who answer when you write, a team that can run a room, and a reason for a stranger to pay attention. A non-profit has to raise its entire budget again every year from scratch. You do not. That asymmetry is the whole opportunity, and it is why the most effective impact work attached to a for-profit looks nothing like charity and everything like operations.
From big idea to red-carpet rollout.
Activate 4 Impact is built on that premise and staffed for it. Strategy, production, execution — worldwide. Eight kinds of work: retreats and offsites, events and experiences, business launch, growth and scale, teams and culture, scale and exit readiness, real estate and development, and tourism and destination activation. Four sectors: government and defence, federal agencies and the public sector, non-profits and movements, and enterprise, hospitality and tourism. It is a R0cketShip Holdings and Crews Beyond Limits company. Krystalore Crews, MBA, is Executive Director — twenty-two years in the U.S. Air Force, retired Senior Master Sergeant, who built a forty-hour Pentagon curriculum and the computer-based training behind it. Jeff Cline is the growth and technology architect.
The division of labour is the part worth stealing even if you never hire anybody. Activate creates the experience — the retreat, the event, the launch, the programme. Amplify uses predictive demand, intent data, SEO, AEO and paid media so the whole market sees it and acts. Two halves, deliberately separate, so neither gets to be an excuse for the other. A moving event nobody hears about is a cost centre. A loud campaign for a mediocre room is worse, because it works once.
And the impact half is not theoretical here. The same team runs Her Next Mission for women leaving service, and worldchangers.ai for founders who want to grow without buying it with their health. One operator, one set of hours, a for-profit and a non-profit fed by the same machinery. That is the argument, and the page opposite is what it looks like when it works.